Forty-Eight US FDA Drug Application Decisions Delayed By Pandemic's Deferred Inspections
Executive Summary
US FDA 'resilience' report charts how inspection backlog grew and impacted approvals and compliance follow-up.
You may also be interested in...
US GDUFA III Talks In Final Stages, Agreement Nearly Complete
Final commitment letter preparations now under way as revenue issues are resolved.
US FDA Gets Less FY2022 Funding From Senate Than House, Different Inspection Priorities
CDER would receive $17m less in Senate appropriations bill compared to House veion, while CFSAN's total would be nearly $10m less. Overall, Senate bill includes around $50.4m less in funding for FDA than House bill.
FDA Would Get Less Funding, Different Inspection Priorities Under Senate Legislation Than House
CDER would lose the most money in the Senate appropriations bill compared to the House version, while CBER would see an increase.